Yu Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu Chang has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Hong-Min Lin
Department of Family Medicine, Chi-Mei Medical Center, Tainan, Taiwan
3 shared publications - Kuan-Yu Chi
Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA
3 shared publications Chien-Min Chen
Changhua Christian Hospital
2 shared publications- Ishmum Chowdhury
Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine , Bronx, NY
2 shared publications - Jung-Shun Lee
Division of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2 shared publications Pang-Shuo Perng
Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University , Tainan
2 shared publications
Latest Publications
- 19 October 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
Defining the TBI spectrum for rib fixation
Was not provided for this article.
- 19 October 2026
- Published by Wolters Kluwer Health in Journal of Trauma and Acute Care Surgery
Defining the TBI spectrum for rib fixation
Was not provided for this article.
- Open Access
- 23 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (5) , 368-378
Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation
Background: Rheumatoid arthritis (RA)–related physical limitations often hinder sustained physical activity and weight management, thereby amplifying cardiovascular risk through adverse metabolic profiles and chronic inflammation. We aimed to assess the effectiveness of semaglutide on the risk of incident major adverse cardiovascular and cerebrovascular events (MACCE) in obese adults with type 2 diabetes mellitus (T2DM) and RA in a primary-prevention setting. Methods: We emulated a target trial using data from the TriNetX US database, including obese adults (aged ≥18 years; BMI ≥30 kg/m2) with T2DM and comorbid RA and no prior history of stroke, heart failure (HF), acute coronary syndrome, or coronary revascularisation. Using a new-user design, we compared patients initiating semaglutide with those initiating non–GLP-1 receptor agonist (GLP-1RA) second-line glucose-lowering therapies. Patients with contraindications to GLP-1RAs were excluded. Propensity-score matching (PS) (1:1) was used to balance baseline covariates. The primary outcome was incident MACCE, defined as a composite of all-cause mortality, myocardial infarction (MI), HF, or stroke. Secondary outcomes included individual MACCE components, HF hospitalisation and disease-modifying antirheumatic drugs (DMARDs) escalation, with Bonferroni correction applied for multiple comparisons. Hazard ratios (HRs) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models over a follow-up of up to 2 years. Results: Between Jan 1, 2014, and Jan 1, 2025, we identified 1,200 and 2,972 patients who initiated semaglutide and non-GLP1RA therapies, respectively, within 3 months of meeting eligibility. After PS matching, 1,017 semaglutide users were compared with 1,017 non–GLP-1RA users (mean age mean age 59.5 vs 59.3 years; women 81.3% vs 81.0%; mean BMI 38.2 vs 38.0 kg/m2; HbA1c, 6.8 vs 7.0%). Semaglutide initiation was associated with a significantly lower risk of incident MACCE compared with non–GLP-1RA therapies (12.7% vs 16.5%; HR, 0.75; 95% CI, 0.60–0.94; P = 0.01). This benefit was driven primarily by a lower risk of incident HF (8.9% vs 12.5%; HR 0.69, 95% CI 0.53–0.91; p=0·007). Semaglutide use was also associated with significantly lower DMARDs escalation (16.6% vs 21.6%; HR, 0.75; 95% CI, 0.60–0.90; P = 0.003. No significant differences were observed in all-cause mortality, MI, or stroke. Conclusion: Among obese adults with T2DM and comorbid RA, initiation of semaglutide was associated with a reduced risk of incident MACCE, driven predominantly by a reduction in incident HF, in a primary-prevention setting. Prospective studies are needed to confirm these observations and establish causality.
- 23 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (5) , 368-378
Open AccessSemaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation
Background: Rheumatoid arthritis (RA)–related physical limitations often hinder sustained physical activity and weight management, thereby amplifying cardiovascular risk through adverse metabolic profiles and chronic inflammation. We aimed to assess the effectiveness of semaglutide on the risk of incident major adverse cardiovascular and cerebrovascular events (MACCE) in obese adults with type 2 diabetes mellitus (T2DM) and RA in a primary-prevention setting. Methods: We emulated a target trial using data from the TriNetX US database, including obese adults (aged ≥18 years; BMI ≥30 kg/m2) with T2DM and comorbid RA and no prior history of stroke, heart failure (HF), acute coronary syndrome, or coronary revascularisation. Using a new-user design, we compared patients initiating semaglutide with those initiating non–GLP-1 receptor agonist (GLP-1RA) second-line glucose-lowering therapies. Patients with contraindications to GLP-1RAs were excluded. Propensity-score matching (PS) (1:1) was used to balance baseline covariates. The primary outcome was incident MACCE, defined as a composite of all-cause mortality, myocardial infarction (MI), HF, or stroke. Secondary outcomes included individual MACCE components, HF hospitalisation and disease-modifying antirheumatic drugs (DMARDs) escalation, with Bonferroni correction applied for multiple comparisons. Hazard ratios (HRs) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models over a follow-up of up to 2 years. Results: Between Jan 1, 2014, and Jan 1, 2025, we identified 1,200 and 2,972 patients who initiated semaglutide and non-GLP1RA therapies, respectively, within 3 months of meeting eligibility. After PS matching, 1,017 semaglutide users were compared with 1,017 non–GLP-1RA users (mean age mean age 59.5 vs 59.3 years; women 81.3% vs 81.0%; mean BMI 38.2 vs 38.0 kg/m2; HbA1c, 6.8 vs 7.0%). Semaglutide initiation was associated with a significantly lower risk of incident MACCE compared with non–GLP-1RA therapies (12.7% vs 16.5%; HR, 0.75; 95% CI, 0.60–0.94; P = 0.01). This benefit was driven primarily by a lower risk of incident HF (8.9% vs 12.5%; HR 0.69, 95% CI 0.53–0.91; p=0·007). Semaglutide use was also associated with significantly lower DMARDs escalation (16.6% vs 21.6%; HR, 0.75; 95% CI, 0.60–0.90; P = 0.003. No significant differences were observed in all-cause mortality, MI, or stroke. Conclusion: Among obese adults with T2DM and comorbid RA, initiation of semaglutide was associated with a reduced risk of incident MACCE, driven predominantly by a reduction in incident HF, in a primary-prevention setting. Prospective studies are needed to confirm these observations and establish causality.
- Open Access
- 15 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (4) , 331-342
Selective serotonin reuptake inhibitors and bleeding risk in patients undergoing PCI on dual antiplatelet therapy: a retrospective cohort study
Aims: Mood disorders are highly prevalent among patients with coronary artery disease; however, pharmacologic treatment with selective serotonin reuptake inhibitors (SSRIs) poses potential bleeding concerns, particularly in patients receiving dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Despite biologic plausibility and observational evidence linking SSRIs to impaired platelet aggregation, data specific to PCI populations remain limited. Methods and results: Using the TriNetX Global Collaborative Network, we identified adults (≥18 years) who underwent PCI with 12 months of DAPT (aspirin plus a P2Y12 inhibitor) between January 2013 and August 2024. Patients were subdivided into SSRI users and non-users. SSRI users were those who had a prescription record within 12 months prior to PCI and refilled records in both the 0- to 6-month and 6- to 12-month periods following index PCI. SSRI non-users were those who had no SSRI prescriptions within 12 months before and after index PCI. Individuals on anticoagulants, serotonin–norepinephrine reuptake inhibitors, or with recent major bleeding were excluded. Propensity-score matching (1:1) was used to balance baseline characteristics between SSRI users and non-users, and time-to-event outcomes were assessed using Kaplan–Meier and Cox proportional-hazards analyses. The primary endpoint was any major bleeding (intracranial haemorrhage [ICH], gastrointestinal bleeding [GIB], requirement for blood transfusion, or other major bleeding) over 1 year; secondary outcomes included ICH, GIB, transfusion, acute myocardial infarction, stroke/TIA, and all-cause mortality Of 29 973 PCI patients on DAPT, 3847 used SSRIs. After matching, 3023 SSRI users were compared with 3023 non-users. Over 1 year, major bleeding occurred in 14.0% of SSRI users vs. 11.3% of non-users (HR 1.28; 95% CI 1.11–1.48; P < 0.001). SSRI use was associated with a significantly higher risk of ICH (1.2% vs. 0.7%; HR 1.73; 95% CI 1.01–2.97; P = 0.043) and GIB (7.4% vs. 5.6%; HR 1.34; 95% CI 1.10–1.63; P = 0.004). Red blood cell transfusion (4.6% vs. 4.1%; HR 1.15; 95% CI 0.90–1.46; P = 0.267), all-cause mortality (4.1% vs. 3.8%; HR 1.08; 95% CI 0.83–1.39; P = 0.573), and ischaemic outcomes were comparable between groups. The association was strongest in patients aged ≥65 years, with hypertension, chronic kidney disease, or concomitant NSAID use and was consistent across ACS and non-ACS presentations. Conclusion: In this large, retrospective, real-world cohort, concomitant SSRI therapy during DAPT was associated with an increased bleeding risk, primarily driven by intracranial and gastrointestinal events, without a corresponding increase in ischaemic outcomes, highlighting the importance of clinical awareness of this pharmacodynamic interaction, particularly in higher-risk subgroups, and underscoring the value of established bleeding prevention strategies in this population.
- 15 May 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (4) , 331-342
Open AccessSelective serotonin reuptake inhibitors and bleeding risk in patients undergoing PCI on dual antiplatelet therapy: a retrospective cohort study
Aims: Mood disorders are highly prevalent among patients with coronary artery disease; however, pharmacologic treatment with selective serotonin reuptake inhibitors (SSRIs) poses potential bleeding concerns, particularly in patients receiving dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). Despite biologic plausibility and observational evidence linking SSRIs to impaired platelet aggregation, data specific to PCI populations remain limited. Methods and results: Using the TriNetX Global Collaborative Network, we identified adults (≥18 years) who underwent PCI with 12 months of DAPT (aspirin plus a P2Y12 inhibitor) between January 2013 and August 2024. Patients were subdivided into SSRI users and non-users. SSRI users were those who had a prescription record within 12 months prior to PCI and refilled records in both the 0- to 6-month and 6- to 12-month periods following index PCI. SSRI non-users were those who had no SSRI prescriptions within 12 months before and after index PCI. Individuals on anticoagulants, serotonin–norepinephrine reuptake inhibitors, or with recent major bleeding were excluded. Propensity-score matching (1:1) was used to balance baseline characteristics between SSRI users and non-users, and time-to-event outcomes were assessed using Kaplan–Meier and Cox proportional-hazards analyses. The primary endpoint was any major bleeding (intracranial haemorrhage [ICH], gastrointestinal bleeding [GIB], requirement for blood transfusion, or other major bleeding) over 1 year; secondary outcomes included ICH, GIB, transfusion, acute myocardial infarction, stroke/TIA, and all-cause mortality Of 29 973 PCI patients on DAPT, 3847 used SSRIs. After matching, 3023 SSRI users were compared with 3023 non-users. Over 1 year, major bleeding occurred in 14.0% of SSRI users vs. 11.3% of non-users (HR 1.28; 95% CI 1.11–1.48; P < 0.001). SSRI use was associated with a significantly higher risk of ICH (1.2% vs. 0.7%; HR 1.73; 95% CI 1.01–2.97; P = 0.043) and GIB (7.4% vs. 5.6%; HR 1.34; 95% CI 1.10–1.63; P = 0.004). Red blood cell transfusion (4.6% vs. 4.1%; HR 1.15; 95% CI 0.90–1.46; P = 0.267), all-cause mortality (4.1% vs. 3.8%; HR 1.08; 95% CI 0.83–1.39; P = 0.573), and ischaemic outcomes were comparable between groups. The association was strongest in patients aged ≥65 years, with hypertension, chronic kidney disease, or concomitant NSAID use and was consistent across ACS and non-ACS presentations. Conclusion: In this large, retrospective, real-world cohort, concomitant SSRI therapy during DAPT was associated with an increased bleeding risk, primarily driven by intracranial and gastrointestinal events, without a corresponding increase in ischaemic outcomes, highlighting the importance of clinical awareness of this pharmacodynamic interaction, particularly in higher-risk subgroups, and underscoring the value of established bleeding prevention strategies in this population.
- 16 February 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (8) , 879-882
Association of postlaminectomy syndrome with cardiovascular events in patients undergoing posterior lumbar fusion
Background: Postlaminectomy syndrome (PLS) is a chronic pain condition characterized by persistent or recurrent symptoms after lumbar spine surgery. Although chronic pain states have been linked to autonomic dysregulation, inflammation, and increased cardiometabolic burden, the long-term cardiovascular implications of PLS remain unclear. Posterior lumbar fusion (PLF) is one of the most common lumbar procedures, providing a clinically relevant population in which to evaluate whether PLS signals broader cardiovascular vulnerability. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network. Adults aged ≥18 years who underwent PLF between 2015 and 2020 were identified by CPT codes. The exposed cohort included individuals with a new diagnosis of PLS (ICD-10 M96.1) occurring ≥6 months after fusion; matched controls were assigned an index encounter at the corresponding postoperative interval. Outcomes included major cardiac events (MCE), stroke, and MACE (MCE + stroke) within 5 years. Propensity score matching was performed based on demographics, comorbidities, and medication use. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: After matching, 6384 patients were included in each cohort. PLS was associated with increased 5-year risk of MACE (12.3% vs 10.8%; OR 1.16, 95% CI 1.04-1.29) and MCE (9.9% vs 8.1%; OR 1.26, 95% CI 1.11-1.42). Stroke risk was not significantly different (OR 1.11, 95% CI 0.92-1.34). Conclusions: PLS after PLF is associated with elevated long-term cardiac risk. These findings suggest PLS may represent a marker of broader systemic vulnerability, warranting enhanced cardiovascular surveillance and multidisciplinary postoperative management.
- 16 February 2026
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 27 (8) , 879-882
Association of postlaminectomy syndrome with cardiovascular events in patients undergoing posterior lumbar fusion
Background: Postlaminectomy syndrome (PLS) is a chronic pain condition characterized by persistent or recurrent symptoms after lumbar spine surgery. Although chronic pain states have been linked to autonomic dysregulation, inflammation, and increased cardiometabolic burden, the long-term cardiovascular implications of PLS remain unclear. Posterior lumbar fusion (PLF) is one of the most common lumbar procedures, providing a clinically relevant population in which to evaluate whether PLS signals broader cardiovascular vulnerability. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network. Adults aged ≥18 years who underwent PLF between 2015 and 2020 were identified by CPT codes. The exposed cohort included individuals with a new diagnosis of PLS (ICD-10 M96.1) occurring ≥6 months after fusion; matched controls were assigned an index encounter at the corresponding postoperative interval. Outcomes included major cardiac events (MCE), stroke, and MACE (MCE + stroke) within 5 years. Propensity score matching was performed based on demographics, comorbidities, and medication use. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: After matching, 6384 patients were included in each cohort. PLS was associated with increased 5-year risk of MACE (12.3% vs 10.8%; OR 1.16, 95% CI 1.04-1.29) and MCE (9.9% vs 8.1%; OR 1.26, 95% CI 1.11-1.42). Stroke risk was not significantly different (OR 1.11, 95% CI 0.92-1.34). Conclusions: PLS after PLF is associated with elevated long-term cardiac risk. These findings suggest PLS may represent a marker of broader systemic vulnerability, warranting enhanced cardiovascular surveillance and multidisciplinary postoperative management.
- Open Access
- 24 September 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (3) , 1418-1422
Association of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score–matched Cohort Study
Study Design: Retrospective propensity score–matched cohort study. Objectives: To investigate whether the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk of lumbar degenerative disease (LDD) and lumbar spine surgery in patients with type 2 diabetes mellitus (T2DM). Methods: Data were obtained from the TriNetX Global Collaborative Network. Adult patients with T2DM initiating GLP-1 RA therapy were matched 1:1 with non-users based on demographics, comorbidities, and medication use. Patients with pre-existing LDD or prior lumbar spine surgery were excluded. Primary outcome was the incidence of LDD; secondary outcome was lumbar spine surgery. Outcomes were assessed at 3- and 5-year intervals, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: A total of 196 435 matched pairs were analyzed. At 3 years, GLP-1 RA users had a lower incidence of LDD (11.9% vs 13.3%; OR 0.89, 95% CI: 0.87-0.91). At 5 years, this difference widened (14.6% vs 18.7%; OR 0.74, 95% CI: 0.73-0.74). Lumbar spine surgery rates were similar at 3 years (0.4% in both groups; OR 1.03, 95% CI: 0.93-1.14), but significantly lower in GLP-1 RA users at 5 years (0.5% vs 0.6%; OR 0.86, 95% CI: 0.78-0.92). Conclusions: GLP-1 RA use is associated with a lower long-term risk of developing LDD and undergoing lumbar spine surgery in patients with T2DM. These findings support further investigation of GLP-1 RAs as potential disease-modifying agents in spinal health.
- 24 September 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (3) , 1418-1422
Open AccessAssociation of GLP-1 Receptor Agonist Use With Risk of Lumbar Degenerative Disease and Spine Surgery in Patients With Type 2 Diabetes: A Propensity Score–matched Cohort Study
Study Design: Retrospective propensity score–matched cohort study. Objectives: To investigate whether the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk of lumbar degenerative disease (LDD) and lumbar spine surgery in patients with type 2 diabetes mellitus (T2DM). Methods: Data were obtained from the TriNetX Global Collaborative Network. Adult patients with T2DM initiating GLP-1 RA therapy were matched 1:1 with non-users based on demographics, comorbidities, and medication use. Patients with pre-existing LDD or prior lumbar spine surgery were excluded. Primary outcome was the incidence of LDD; secondary outcome was lumbar spine surgery. Outcomes were assessed at 3- and 5-year intervals, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: A total of 196 435 matched pairs were analyzed. At 3 years, GLP-1 RA users had a lower incidence of LDD (11.9% vs 13.3%; OR 0.89, 95% CI: 0.87-0.91). At 5 years, this difference widened (14.6% vs 18.7%; OR 0.74, 95% CI: 0.73-0.74). Lumbar spine surgery rates were similar at 3 years (0.4% in both groups; OR 1.03, 95% CI: 0.93-1.14), but significantly lower in GLP-1 RA users at 5 years (0.5% vs 0.6%; OR 0.86, 95% CI: 0.78-0.92). Conclusions: GLP-1 RA use is associated with a lower long-term risk of developing LDD and undergoing lumbar spine surgery in patients with T2DM. These findings support further investigation of GLP-1 RAs as potential disease-modifying agents in spinal health.
- Open Access
- 24 June 2024
- Published by SAGE Publications in Global Spine Journal
- Vol. 15 (2) , 1367-1374
Erector Spinae Plane Block Versus Thoracolumbar Interfascial Plane Block in Lumbar Spine Surgery: A Meta-Analysis of Randomized Controlled Trials
Study Design: Meta-analysis. Objective: To compare the effectiveness of postoperative pain control between erector spinae plane block (ESPB) and thoracolumbar interfascial plane (TLIP) block in lumbar spine surgery. Methods: PubMed, Embase, and MEDLINE electronic databases were searched for articles containing randomized controlled trials (RCTs) published between January 1900 and January 2024. We extracted the postoperative mean pain score, the first 24-h postoperative morphine consumption, and their standard deviation from the included studies. Meta-analysis was performed using the functions available in the metafor package in R software. We pooled continuous variables using an inverse variance method with a random-effects model and summarized them as standardized mean differences. Results: Five RCTs that directly compared the ESPB and TLIP block in lumbar spine surgery were included, enrolling 432 participants randomly into the two groups with 216 participants in each group. The pooled analyses showed that there was no significant difference between the ESPB and TLIP groups in terms of lower pain scores during the early (1 h) (standardized mean difference [SMD] −1.49, 95% confidence interval [CI], −3.10; 0.11), middle (12 h) (SMD −3.12, 95% CI, −6.86; 0.61), and late (24 h) (SMD −1.38, 95% CI, −3.01; 0.24) postoperative periods. There was also no significant difference in the first 24-h postoperative morphine equivalent consumption between the ESPB and TLIP groups (SMD −0.46 mg, 95% CI −1.23; 0.31). Conclusion: No significant difference was observed between the ESPB and TLIP block in terms of postoperative pain control and 24-h morphine equivalent consumption for lumbar spine surgery.
- 24 June 2024
- Published by SAGE Publications in Global Spine Journal
- Vol. 15 (2) , 1367-1374
Open AccessErector Spinae Plane Block Versus Thoracolumbar Interfascial Plane Block in Lumbar Spine Surgery: A Meta-Analysis of Randomized Controlled Trials
Study Design: Meta-analysis. Objective: To compare the effectiveness of postoperative pain control between erector spinae plane block (ESPB) and thoracolumbar interfascial plane (TLIP) block in lumbar spine surgery. Methods: PubMed, Embase, and MEDLINE electronic databases were searched for articles containing randomized controlled trials (RCTs) published between January 1900 and January 2024. We extracted the postoperative mean pain score, the first 24-h postoperative morphine consumption, and their standard deviation from the included studies. Meta-analysis was performed using the functions available in the metafor package in R software. We pooled continuous variables using an inverse variance method with a random-effects model and summarized them as standardized mean differences. Results: Five RCTs that directly compared the ESPB and TLIP block in lumbar spine surgery were included, enrolling 432 participants randomly into the two groups with 216 participants in each group. The pooled analyses showed that there was no significant difference between the ESPB and TLIP groups in terms of lower pain scores during the early (1 h) (standardized mean difference [SMD] −1.49, 95% confidence interval [CI], −3.10; 0.11), middle (12 h) (SMD −3.12, 95% CI, −6.86; 0.61), and late (24 h) (SMD −1.38, 95% CI, −3.01; 0.24) postoperative periods. There was also no significant difference in the first 24-h postoperative morphine equivalent consumption between the ESPB and TLIP groups (SMD −0.46 mg, 95% CI −1.23; 0.31). Conclusion: No significant difference was observed between the ESPB and TLIP block in terms of postoperative pain control and 24-h morphine equivalent consumption for lumbar spine surgery.
- Open Access
- 14 March 2024
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 40 (4) , 395-403
Surgical excision and radiotherapy for brain metastasis from colorectal cancer: How frailty and comorbidity indices influence outcome
The incidence of brain metastasis (BM) from colorectal cancer (CRC) is increasing. This study aims to identify the clinical prognosticators and evaluate the prognostic validity of common comorbidity indices in patients with BM from CRC. This retrospective single-center study analyzed 93 patients with BM from CRC who received surgical excision and/or radiotherapy. The clinical characteristics and prognostic indices including the 5-item modified frailty index (mFI-5) and prognostic nutritional index (PNI) were calculated from the collected patient data and analyzed. In this study, 66 (71.0%), 10 (10.8%), and 17 (18.3%) patients received whole-brain radiotherapy (WBRT) alone, surgery alone, and surgery plus WBRT, respectively. The median survival of all patients was 3.98 months (IQR: 1.74-7.99). The 2- and 3-year survival rates were 7.4% and 3.7%, respectively. Controlled primary tumor (p = 0.048), solitary BM (p = 0.001), surgery + radiation (p < 0.001), and greater PNI (p = 0.001) were independent predictors of favorable survival. In surgically treated patients, uncontrolled primary tumor (p = 0.006), presence of multiple BM (p < 0.001), and MFI-5 ≥ 2 (p = 0.038) were independent prognosticators. For patients who received WBRT, the presence of two (p = 0.004) or multiple (p < 0.001) BM and PNI (p < 0.001) were independent survival predictors MFI-5, multiple BM, and the status of the primary tumor were independent prognosticators for patients who underwent surgery for CRCBM. For patients who received WBRT, the PNI and the number of BM were independent survival predictors.
- 14 March 2024
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 40 (4) , 395-403
Open AccessSurgical excision and radiotherapy for brain metastasis from colorectal cancer: How frailty and comorbidity indices influence outcome
The incidence of brain metastasis (BM) from colorectal cancer (CRC) is increasing. This study aims to identify the clinical prognosticators and evaluate the prognostic validity of common comorbidity indices in patients with BM from CRC. This retrospective single-center study analyzed 93 patients with BM from CRC who received surgical excision and/or radiotherapy. The clinical characteristics and prognostic indices including the 5-item modified frailty index (mFI-5) and prognostic nutritional index (PNI) were calculated from the collected patient data and analyzed. In this study, 66 (71.0%), 10 (10.8%), and 17 (18.3%) patients received whole-brain radiotherapy (WBRT) alone, surgery alone, and surgery plus WBRT, respectively. The median survival of all patients was 3.98 months (IQR: 1.74-7.99). The 2- and 3-year survival rates were 7.4% and 3.7%, respectively. Controlled primary tumor (p = 0.048), solitary BM (p = 0.001), surgery + radiation (p < 0.001), and greater PNI (p = 0.001) were independent predictors of favorable survival. In surgically treated patients, uncontrolled primary tumor (p = 0.006), presence of multiple BM (p < 0.001), and MFI-5 ≥ 2 (p = 0.038) were independent prognosticators. For patients who received WBRT, the presence of two (p = 0.004) or multiple (p < 0.001) BM and PNI (p < 0.001) were independent survival predictors MFI-5, multiple BM, and the status of the primary tumor were independent prognosticators for patients who underwent surgery for CRCBM. For patients who received WBRT, the PNI and the number of BM were independent survival predictors.